10x Genomics shows a gross margin of 71.9%, an operating margin of -11.7%, an EBITDA margin of -2.9%, and a net margin of -10.8%, but its operating margin is negative at -11.7%, its EBITDA margin is negative at -2.9%, and its net margin is negative at -10.8%. All reported margins improved year over year, led by gross margin with an increase of 3.1 percentage points.
Over the last 3 years, 10x Genomics's margins averaged 68.11% gross, -24.13% operating, -14.19% EBITDA, and -21.98% net. All four current margins are above their three-year averages.
All available margins expanded year over year, led by gross margin with an increase of 3.1 percentage points.
Across the last 3 years, 10x Genomics's gross margin averaged 68.11%. The current gross margin stands at 71.9%, 3.8 percentage points above its three-year average. Gross margin was highest at 71.9% in Sep 2026 and lowest at 64.6% in Mar 2024.
The average operating margin for 10x Genomics was -24.13% over the last 3 years. 10x Genomics currently reports an operating margin of -11.7%, 12.4 percentage points above its three-year average. The operating margin for 10x Genomics moved between -43.9% in Mar 2024 and -6.1% in Mar 2026.
Over the last 3 years, 10x Genomics's EBITDA margin averaged -14.19%. At present, 10x Genomics's current EBITDA margin is -2.9%, which is 11.3 percentage points above its three-year average. During this period, EBITDA margin reached a high of 4.2% in Mar 2026 and a low of -33.6% in Mar 2024.
In the last 3 years, 10x Genomics had an average net margin of -21.98%. 10x Genomics currently reports a net margin of -10.8%, 11.2 percentage points above its three-year average. Looking back over the last 3 years, 10x Genomics's net margin reached -3.5% at its highest point in Mar 2026 and -42.3% at its lowest in Mar 2024.
With a gross margin of 71.9%, TXG ranks higher than the Healthcare sector and the industry average. But in comparison with the Healthcare sector average of 68.6%, 10x Genomics's gross margin is only 4.8% higher.
As of Sep 30, 2026, TXG has a gross margin of 71.9%.
As of Sep 30, 2026, TXG has a negative operating margin of -11.7%.
As of Sep 30, 2026, TXG has an EBITDA margin of -2.9%.
For the period ending Sep 30, 2026, TXG recorded a net margin of -10.8%.
10x Genomics's average margins over the last 3 years were 68.1% gross, -24.1% operating, -14.2% EBITDA, and -22.0% net.
In the last 5 years, the highest margins reported by TXG were 84.9% gross in Dec 2021, -6.1% operating in Mar 2026, 4.2% EBITDA in Mar 2026, and -3.5% net in Mar 2026.
Within the 5-year period, TXG recorded its lowest margins at 64.6% gross in Mar 2024, -43.9% operating in Mar 2024, -33.6% EBITDA in Mar 2024, and -42.3% net in Mar 2024.